Clinigen Group Completes Acquisition of iQone Healthcare

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the global pharmaceutical and services company, announces that it has today completed the acquisition of iQone Healthcare Holding ('iQone'), which was announced on 27 September 2018 (the "Acquisition").

Following the admission to AIM earlier today of the 241,744 new ordinary shares of 0.1p each, issued by Clinigen to satisfy part of the initial consideration for the Acquisition, the Company now has in issue 132,191,498 ordinary shares of 0.1p each, with voting rights. Clinigen does not hold any shares in treasury. This figure of 132,191,498 ordinary shares may be used by shareholders in Clinigen to determine if they are required to notify their interest in, or a change in their interest in, Clinigen under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information, please contact:

Clinigen Group plc
Shaun Chilton, Group Chief Executive
Martin Abell, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
Tel:+44 (0) 1283 495 010

Numis Securities Limited
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
Tel: +44 (0)20 7260 1000

RBC Capital Markets - Joint Broker
Marcus Jackson / Elliot Thomas
Tel: +44 (0)20 7653 4000

Instinctif Partners
Adrian Duffield / Melanie Toyne-Sewell / Alex Shaw
Tel: +44 (0)20 7457 2020

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

For more information, please visit www.clinigengroup.com